



**CONSEGNA**  
DELIVERING INNOVATION

## CONSEGNA \$510,000 R&D TAX INCENTIVE TO SUPPORT BREATHEASSIST DEVELOPMENT

---

### Highlights:

- **R&D registration approved by Innovation Australia**
- **R&D rebate of approximately \$510,000**

**Melbourne, Wednesday 24th April 2013.** Consegna Group Limited (ASX:CGP), a leading Australian respiratory technology and nasal drug delivery company expects to receive a cash payment of approximately \$510,000 this quarter to support the continued development of its BreatheAssist™ technology.

Innovation Australia has approved the registration of Consegna's Research and Development application for the 2012 financial year R&D Tax Incentive Scheme. Under the legislation Consegna can claim a tax credit and receive a refund from the government for up to 45 per cent of its eligible R&D spend.

For the 2012 financial year, Consegna claimed \$1,146,227 of eligible R&D expenditure, which entitles the Company to apply for a cash rebate of \$515,802 from the Australian Taxation Office.

Consegna's new Executive Director, Michael Johnson commented on the R&D registration, *"Receiving the registration from AusIndustry is a strong indication that our R&D activities have been lodged correctly and we are a step closer to receiving a substantial, non-dilutive boost to our funds as we embark on the renewed commercialisation strategies for BreatheAssist."*

### Enquiries:

Michael Johnson - Executive Director  
m: 0417 395 550

